Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections

Candida auris is an emerging multidrug-resistant fungal pathogen reported worldwide. Infections due to C. auris are usually nosocomial and associated with high rates of fluconazole resistance and mortality. Echinocandins are utilized as the first-line treatment. However, echinocandins are only avail...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghannoum, Mahmoud, Arendrup, Maiken Cavling, Chaturvedi, Vishnu P., Lockhart, Shawn R., McCormick, Thomas S., Chaturvedi, Sudha, Berkow, Elizabeth L., Juneja, Deven, Tarai, Bansidhar, Azie, Nkechi, Angulo, David, Walsh, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559578/
https://www.ncbi.nlm.nih.gov/pubmed/32854252
http://dx.doi.org/10.3390/antibiotics9090539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559578/
https://www.ncbi.nlm.nih.gov/pubmed/32854252
http://dx.doi.org/10.3390/antibiotics9090539

Ejemplares similares